{"database": "lobbying", "table": "lobbying_activities", "rows": [[3188060, "6cb41732-f98c-4ac9-948f-699318899057", "Q2", "MARSHALL & POPP, LLC", 401105121, "AMGEN USA INC.", 2024, "second_quarter", "CPT", "Issues related to intellectual property and patent reform, including: S. 150, Affordable Prescriptions for Patients Act; S. 79, Interagency Patent Coordination and Improvement Act; S. 113, Prescription Pricing for the People Act; S. 142, Preserve Access to Affordable Generics and Biosimilars Act; and S. 148, Stop STALLING Act. Issues related to the National Institute of Standards and Technology request for public comment on a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2024-07-10T14:48:35-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["3188060"], "units": {}, "query_ms": 21.19652391411364, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}